PRTG Profile
Portage Biotech Inc., headquartered in Tortola, British Virgin Islands, is an innovative pharmaceutical and biotechnology company dedicated to the development of cutting-edge treatments for cancer and other serious diseases. The company focuses on advancing a diverse portfolio of therapeutic products, leveraging its proprietary technologies and platforms to address significant unmet medical needs. Portage Biotech is at the forefront of research in immuno-oncology and novel drug delivery systems, with a strong emphasis on developing therapies that enhance immune response and target cancer cells more effectively.
Among Portage Biotech's notable products are IMM60 and IMM65. IMM60 is an iNKT cell activator designed to stimulate and enhance the body’s natural immune response against cancer cells. IMM65 combines a PLGA nanoparticle with a NY-ESO-1 peptide vaccine, aimed at eliciting a targeted immune response against tumors expressing the NY-ESO-1 antigen. The company’s portfolio also includes several adenosine receptor inhibitors, such as TT-10, TT-4, TT-53, and TT-3, which are designed to disrupt the adenosine signaling pathway in tumors. These inhibitors target different adenosine receptors (A2A and A2B) and are intended for the treatment of various solid tumors, including colorectal and gastrointestinal cancers.
Portage Biotech is advancing NT230-6, which is currently undergoing Phase I/II clinical trials. This promising candidate is being evaluated for its efficacy in treating a range of tumors. Additionally, the company has developed the Nanolipogel (NLG) co-formulation platform, which facilitates the delivery of DNA aptamers and aptamer-small molecule combination products. This platform is designed to improve the precision and effectiveness of therapeutic interventions. Portage Biotech also utilizes its STING agonist platform, a proprietary technology that enhances immune priming and boosting, offering innovative approaches to stimulate immune responses against cancer.
The company's robust pipeline and advanced technologies underscore its commitment to pioneering new therapeutic options and addressing critical challenges in cancer treatment. By harnessing its expertise in immuno-oncology and drug delivery systems, Portage Biotech aims to make a significant impact in the field of biotechnology and improve patient outcomes through its innovative product offerings.
|
